Across the recent three months, 5 analysts have shared their insights on Axogen (NASDAQ:AXGN), expressing a variety of opinions spanning from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.8, along with a high estimate of $26.00 and a low estimate of $22.00. This upward trend is apparent, with the current average reflecting a 12.73% increase from the previous average price target of $22.00.

Understanding Analyst Ratings: A Comprehensive Breakdown

The perception of Axogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axogen's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Axogen analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Axogen

Key Indicators: Axogen's Financial Health

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Axogen's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 15.1%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Axogen's net margin is impressive, surpassing industry averages. With a net margin of 0.91%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Axogen's ROE stands out, surpassing industry averages. With an impressive ROE of 0.44%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Axogen's ROA excels beyond industry benchmarks, reaching 0.23%. This signifies efficient management of assets and strong financial health.

Debt Management: Axogen's debt-to-equity ratio surpasses industry norms, standing at 0.66. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.